Cholinergic-dependent cognitive deficits in Parkinson's disease
- PMID: 3631918
- DOI: 10.1002/ana.410220108
Cholinergic-dependent cognitive deficits in Parkinson's disease
Abstract
In a double-blind cross-over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.
Similar articles
-
Cholinergic deficiency and frontal dysfunction in Parkinson's disease.Ann Neurol. 1990 Aug;28(2):117-21. doi: 10.1002/ana.410280202. Ann Neurol. 1990. PMID: 2221841
-
[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. Encephale. 2008. PMID: 19081451 French.
-
Aging and cholinergic modulation of the transient magnetic 40-Hz auditory response.Neuroimage. 2002 Jan;15(1):153-8. doi: 10.1006/nimg.2001.0956. Neuroimage. 2002. PMID: 11771983 Clinical Trial.
-
Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar;29(3):411-22. doi: 10.1016/j.pnpbp.2004.12.008. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15795050 Review.
-
[Cognitive deficits in Parkinson's disease].Rev Neurol (Paris). 1991;147(5):337-55. Rev Neurol (Paris). 1991. PMID: 1853032 Review. French.
Cited by
-
Cognitive effects of scopolamine in dementia.J Neural Transm (Vienna). 1996;103(7):873-81. doi: 10.1007/BF01273365. J Neural Transm (Vienna). 1996. PMID: 8872871 Clinical Trial.
-
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.Rev Neurosci. 2013;24(3):267-78. doi: 10.1515/revneuro-2013-0004. Rev Neurosci. 2013. PMID: 23729617 Free PMC article. Review.
-
Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.J Neurol. 2006 Feb;253(2):242-7. doi: 10.1007/s00415-005-0971-0. Epub 2005 Sep 2. J Neurol. 2006. PMID: 16133720
-
Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.Neurodegener Dis. 2013;11(2):79-92. doi: 10.1159/000341998. Epub 2012 Oct 3. Neurodegener Dis. 2013. PMID: 23038420 Free PMC article. Review.
-
Anticholinergics for symptomatic management of Parkinson's disease.Cochrane Database Syst Rev. 2003;2002(2):CD003735. doi: 10.1002/14651858.CD003735. Cochrane Database Syst Rev. 2003. PMID: 12804486 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical